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Abstract: Anemia is a common complication of systemic anti-cancer treatment. In this context 
epoetin beta, like other erythropoiesis-stimulating agents (ESAs), has demonstrable efﬁ  cacy in 
raising Hb concentration and reducing the requirement for red cell transfusion. Consequently 
ESA therapy has gained increasing prominence in the management of chemotherapy-related 
anemia. However, recent trial data have suggested a higher rate of thromboembolic events, 
enhanced tumor progression and reduced survival in some patients with cancer who receive 
ESA therapy. In response, regulatory authorities have mandated increasingly restrictive label 
changes. In light of these new developments we consider the current role of epoetin beta in the 
management of chemotherapy-related anemia.
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Introduction
Anemia, deﬁ  ned as a hemoglobin (Hb) concentration below the lower limit of normal, 
is common in patients with cancer and may be either disease or treatment-related. The 
World Health Organization (WHO), National Cancer Institute (NCI), and the Eastern 
Co-operative Oncology Group (ECOG) differ slightly in their classiﬁ  cation of mild 
to moderate anemia although there is concordance on the deﬁ  nition of severe anemia 
as a Hb level  8.0 g/dL (Table 1).
There are many potential causes of anemia in a patient with cancer.1 Commonly 
cancer-related anemia can be attributed to the syndrome of anemia of chronic disease 
(ACD) which is mediated by pro-inﬂ  ammatory cytokines and characterized by impaired 
iron utilization, reduced erythropoietin (EPO) mRNA synthesis and reduced RBC 
lifespan.2 This diagnosis requires exclusion of other possible causes, such as occult 
bleeding, iron or vitamin deﬁ  ciency, autoimmune hemolysis or marrow inﬁ  ltration. 
Alternatively anemia may be caused by cancer treatment itself. For example, severe 
or life-threatening anemia occurs in up to 40% of patients receiving platinum-based 
chemotherapy for lung cancer.3 Chemotherapy-related anemia primarily reﬂ  ects 
cytotoxicity to erythroid precursors in the marrow although for certain agents such 
as platinums, toxicity to erythropoietin producing cells in the kidney is also relevant. 
Chemotherapy-related anemia is cumulative with increasing incidence over succes-
sive courses of treatment. For example, in an audit of patients receiving chemotherapy 
for solid tumors at 28 centers in the United Kingdom anemia (in this case deﬁ  ned as 
Hb   11 g/dL) was present in 17% of patients prior to the ﬁ  rst cycle, rising to 38% 
by the sixth.4
Incidence of anemia in cancer
Several long-standing difﬁ  culties hindered attempts to deﬁ  ne the true incidence of 
anemia in patients with cancer; for example, the lack of standardized toxicity criteria 
and the under-reporting of mild to moderate anemia due to a perceived lack of clinical Therapeutics and Clinical Risk Management 2009:5 262
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importance as well as a lack of treatment options.3 It is only 
in the last 10 years that efforts such as the European Cancer 
Anemia Survey (ECAS) have signiﬁ  cantly advanced our 
understanding of anemia related to cancer and its treatment.5 
ECAS prospectively evaluated the prevalence and incidence 
of anemia (deﬁ  ned as Hb   12 g/dL) in over 15,000 cancer 
patients from 748 European cancer treatment centers. Overall 
67.9% of patients were found to be anemic at least once 
during the study. In patients with normal Hb at enrolment 
the incidence of anemia was 53.7% overall, and was 62.7% 
in those patients who received chemotherapy. Of interest was 
the possible under-treatment of anemia identiﬁ  ed by ECAS. 
For example, 61.1% of patients who were ever anemic did not 
receive treatment for anemia. Of these 47.2% had Hb levels of 
10 – 11.9 g/dL but 12.9% had a Hb between 8.0 and 9.9 g/dL 
with 0.9% having Hb   8.0 g/dL. Furthermore, over half of 
anemic patients with WHO performance score   2 did not 
receive treatment for their anemia.
ECAS also deﬁ  ned the marked variation in both the preva-
lence and treatment of anemia across different cancer types. 
Unsurprisingly hematological malignancies produced the 
highest incidences of anemia at 52% to 53% for lymphoma, 
myeloma, and leukemia. Of the solid tumors, anemia was most 
common in gynecological (49%) and lung cancers (38%). This 
may reﬂ  ect the higher use of platinum containing regimes in 
ovarian and lung cancers. As many as 73.8% of breast cancer 
patients were not given treatment following an episode of 
anemia, with leukemic patients as the only cancer group who 
received treatment for anemia over 50% of the time.
Symptoms of anemia and impact 
on quality of life (QoL)
The most common symptom attributed to anemia is fatigue. 
Other symptoms and signs include dyspnoea, palpitations, 
headache, dizziness, chest pain, depression and tachycardia. 
Furthermore, chronic anemia may cause end-organ damage, 
affecting particularly the cardiovascular system, lungs, 
kidneys, and central nervous system.6 Anemia may be 
particularly debilitating in cancer patients with existing 
co-morbidities such as chronic obstructive pulmonary disease 
or ischemic heart disease. 7 Many of the symptoms of anemia 
are non-speciﬁ  c and, in some patients, will be attributable 
to the underlying malignancy itself rather than reﬂ  ecting the 
presence of anemia. Despite this a signiﬁ  cant correlation 
between Hb concentration and QoL has been demonstrated in 
patients with cancer, although factors other than anemia such 
as pain and sleep disturbance are also of importance.8,9
Relationship of anemia to cancer 
outcomes
Anemia is well recognized as an independent adverse prog-
nostic factor in various cancers. These include head and 
neck, lung, prostate, cervical and hematological malignan-
cies.10 Similarly, intra-tumoral hypoxia has also been linked 
to poor outcome, although it should be acknowledged that 
the relationship between anemia and intra-tumoral hypoxia 
is complex.11 These observations have led to the hypothesis 
that correction of anemia may have the potential not only 
to improve QoL but also to improve response to anticancer 
therapy and survival. Nonetheless, despite the biological 
plausibility of a causal link between anemia/intra-tumoral 
hypoxia and poor outcome the existence of such a relation-
ship remains unproven. In particular, whether situations 
exist where anti-cancer therapy may be potentiated by 
the correction of anemia remains contentious. A provoca-
tive retrospective analysis of 494 patients who received 
chemo-radiotherapy for cervical cancer in two GOG trials 
suggested that on-treatment, but not baseline, Hb concentra-
tion was predictive of disease progression thus generating 
the hypothesis that there may be an interaction between 
anemia and treatment efﬁ  cacy in this setting.12 Another ret-
rospective analysis, conducted by Grogan and colleagues, 
suggested that correction of anemia by RBC transfusion 
might overcome the negative prognostic effects of low Hb 
in patients receiving radiotherapy for cervical carcinoma.13 
This strategy has not been tested prospectively although, as 
discussed below, a prospective study evaluating recombi-
nant erythropoietin (hereafter referred to as epoetin) beta 
in a related context failed to demonstrate improved tumor 
control or survival despite effectively raising Hb.14 Likewise, 
retrospective data which suggested improved tumor control 
and survival for correction of anemia in patients receiving 
neoadjuvant chemo-radiotherapy for locally advanced head 
and neck cancer have yet to be conﬁ  rmed prospectively.15 
Table 1 Grading systems used in cancer-related anemia
Hb level (g/dL)
Grade NCI WHO ECOG
0 Normal limits  11.0 Normal limits
1 10.0 to normal 9.5–10.9 10.0 to normal
2 8.0–10.0 8.0–9.4 8.0–10.0
3 6.5–7.9 6.5–7.9 6.5–7.9
4  6.5  6.5  6.5
Abbreviations: NCI, National Cancer Institute;   WHO, World Health Organization; 
ECOG, Eastern Co-operative Oncology Group.Therapeutics and Clinical Risk Management 2009:5 263
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Accordingly, whilst the goal of enhanced treatment efﬁ  cacy 
by correction of anemia remains attractive, proof of principle 
for this approach is outstanding.
Treatment of anemia in cancer
RBC transfusions have historically been the standard treat-
ment for cancer- and cancer treatment-related anemia and 
offer a rapid and effective therapeutic intervention. Since 
the 1990s several erythropoiesis stimulating agents (ESAs) 
including epoetin beta have been approved for the treatment 
of chemotherapy-related anemia. However, given that the 
median time to response for ESAs is measured in weeks 
RBC transfusion has remained the treatment of choice for 
severe anemia. RBC transfusion is associated with several 
potentially life-threatening hazards all of which have a low 
and well quantiﬁ  ed level of risk.16 These include trans-
mission of bacterial or viral infection, transfusion related 
reactions and iron overload. A further consideration is the 
ﬁ  nite supply of donor blood and the need to conserve this 
scare resource.
Epoetin beta
Physiology of human erythropoietin
Human EPO is an acidic glycoprotein hormone, predomi-
nantly produced in the kidney and, to a lesser extent, the 
liver.17,18 Intracellular hypoxia causes increased transcription 
of EPO in a HIF-2α-dependent manner.19 Subsequent binding 
of EPO to its receptor on erythroid progenitor cells activates 
anti-apoptotic pathways resulting in a net increase in RBC 
production.20 In addition, the EPO receptor (EPO-R) is also 
known to be expressed by many non-erythroid cell lineages. 
In-keeping with this observation EPO has recently emerged 
as an important regulator of development, angiogenesis and 
wound healing as well as having important neuro-protectant 
and cardiovascular-protectant properties.21
Epoetin beta
Epoetin beta (NeoRecormon®; F. Hoffmann-La Roche Ltd, 
Basel, Switzerland) is a glycoprotein manufactured by recom-
binant DNA technology to have an amino acid and carbohy-
drate composition indistinguishable from human EPO.22 It 
is approved within the European Union for the treatment of 
symptomatic anemia in adult patients with non-myeloid malig-
nancies receiving chemotherapy. Other licensed indications 
include the treatment of symptomatic anemia associated with 
chronic renal failure in adult and pediatric patients, increasing 
the yield of autologous blood from patients in a pre-donation 
programme, and in prevention of the anemia of prematurity.
Pharmacokinetics and dosing 
of epoetin beta
Epoetin beta, when administered by subcutaneous injection, 
has a bioavailability of 23% to 42%. Maximum serum 
concentration is reached after an average of 12 to 28 hours, 
with a terminal half-life of 13 to 28 hours.22 Previously epoetin 
beta was administered by subcutaneous injection three-
times-weekly to achieve a total weekly dose of 30,000 IU 
(approximately 450 IU/kg), a regimen developed within the 
context of renal dialysis. This has largely been superseded by a 
more convenient once-weekly dosing regimen for which simi-
lar efﬁ  cacy to 3-times-weekly dosing has been demonstrated 
in patients with both hematological and solid tumors.23,24 Dose 
modiﬁ  cation may be required depending on hematological 
response as per the product label.22 The aim should be to use 
the lowest possible dose of epoetin to gradually increase the 
Hb concentration to avoid the need for transfusion.25
Efﬁ  cacy of epoetin beta
The efﬁ  cacy of ESA therapy can be evaluated in several 
ways. The simplest and most direct measure is to demon-
strate a rise in Hb levels. In this regard clinical trials have 
often utilized “Hb response”, deﬁ  ned as an increase in Hb 
concentration of at least 2 g/dL as an endpoint. However, 
more meaningful clinical endpoints include reduced transfu-
sion requirement and improved quality of life. A series of 
systematic reviews and meta-analysis have considered the 
efﬁ  cacy of ESA therapy, generally without discriminating 
between particular agents within this class. Although there 
are no published data regarding the comparative efﬁ  cacy of 
epoetin-beta with epoetin-alfa or darbepoetin these agents are 
considered by regulatory agencies and professional bodies 
as belonging to a single class without signiﬁ  cant difference 
in pharmacodynamics, clinical indications for use, efﬁ  cacy 
or toxicity when used at recommended doses.26
Efﬁ  cacy: hematological responses 
and transfusion requirements
The efﬁ  cacy of epoetin beta in achieving hematological 
response and reducing transfusion requirements in patients 
receiving cancer treatment has been well deﬁ  ned in several 
randomized studies14,27–34 and meta-analyses.35–38 An example 
is the recently reported BRAVE trial which randomly assigned 
463 woman receiving chemotherapy for metastatic breast 
cancer to epoetin-beta or supportive care.34 The mean increase 
in Hb from baseline was 1.3 g/dL in the epoetin group with a 
decrease of 0.4 g/dL in the control group. Epoetin therapy was Therapeutics and Clinical Risk Management 2009:5 264
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associated with a signiﬁ  cant reduction in blood transfusion 
from 27% of patients in the control arm to 14% in the epoetin 
arm (p   0.001). For the subgroup of patients with baseline Hb 
less that 11 g/dL, 45.9% of patients in the control arm required 
transfusion versus 29% in the epoetin arm. Similarly, Strauss 
et al randomized 74 patients receiving radio-chemotherapy for 
cervical cancer to epoetin-beta or supportive care.14 By week 4 
the median Hb had increased by 1.1 g/dL in the epoetin group 
but fallen by 0.6 g/dL in the control group. In both of these 
trials the improvements in Hb were shown to be maintained 
throughout the treatment period.
Boogaerts and colleagues conducted a meta-analysis of 
three trials in which patients undergoing chemotherapy for 
solid tumors received epoetin-beta.39 The median increase 
in Hb level at 16 weeks was 1.5 g/dL in the treatment group 
with no change in the control group. This was associated with 
a 53% reduction in the risk of receiving a transfusion. The 
magnitude of Hb rise was similar whether patients received 
platinum or non-platinum based chemotherapy. The beneﬁ  ts 
of epoetin in raising Hb and reducing risk of transfusion were 
seen as early as 4 weeks.
A recent Health Technology Assessment commissioned 
by the United Kingdom National Institute for Health Research 
(which itself updated an earlier Cochrane review35) considered 
46 RCTs containing 7304 patients comparing ESAs plus sup-
portive care versus supportive care alone.38 The majority of 
trials utilized ESAs in conjunction with anti-cancer therapy 
although 4 trials included patients receiving no anti-cancer 
therapy. Ten of the 46 trials related speciﬁ  cally to epoetin-beta. 
In this meta-analysis 53% of patients receiving ESAs achieved 
a hematological response compared with 15.7% of control 
patients. Overall the pooled relative risk for hematological 
response was 3.40 (95% CI, 3.01–3.83) in favor of ESAs whilst 
the mean difference in overall change in Hb concentrations 
between intervention and control arms was 1.63 g/dL (95% CI, 
1.46–1.8) in favor of ESAs. The relative risk for receiving blood 
transfusion was 0.63 (95% CI, 0.58–0.67) in favor of ESAs 
with transfusion occurring in 30.6% of patients receiving ESAs 
compared to 48.7% of control patients. ESA use was associated 
with a mean difference of 1.05 units of blood transfused.
Taken together these data clearly indicate that ESAs as a 
class, and epoetin beta speciﬁ  cally, are effective at achieving 
hematological response in more than 50% of patients and allow 
for a modest but signiﬁ  cant reduction in blood transfusion.
Efﬁ  cacy: quality of life
Studies of epoetin beta and other ESAs have utilized a vari-
ety of validated tools to assess QoL. These include FACT 
(Functional Assessment of Cancer Treatment) questionnaires 
incorporating additional questions relating to fatigue (FACT-F) 
or anemia (FACT-An), visual analogue scales and other ques-
tionnaires such as SF-36. 35 Although interesting, initial reports 
of improved QoL were based on open label single arm studies 
and thus comprised only low level evidence.40,41 However, 
subsequent double-blind randomized placebo-controlled stud-
ies have conﬁ  rmed improvements in QoL with ESA therapy 
(summarized by Wilson and colleagues38). For example, 
Osterborg and colleagues reported statistically signiﬁ  cant 
increases in FACT-An and FACT-G scales in transfusion-
dependent patients with lymphoproliferative malignancy after 
12 and 16 weeks of treatment with epoetin beta compared to 
those patients who received placebo.30 The improvement in 
QoL correlated with the increase in Hb concentration. These 
data are inkeeping with another randomized double-blind pla-
cebo-controlled trial in which 375 anemic patients receiving 
chemotherapy were randomized to epoetin-alfa or placebo.42 
Again there was a signiﬁ  cant increase in QoL scores in the 
treatment arm with a strong correlation between change in 
Hb concentration and change in QoL. Despite such results 
in individual trials, concerns with the validity of QoL data in 
many studies together with the diversity in QoL scales used 
has led several groups to conclude that meaningful quantitative 
meta-analysis is not possible.36,43 Allowing for this the recent 
HTA systematic review utilized a qualitative vote counting 
approach to conclude that available data indicated a positive 
effect for ESA therapy on QoL, albeit the magnitude of this 
effect was poorly deﬁ  ned.38
Safety and tolerability
The safety proﬁ  le of ESAs remains a highly contentious 
issue.44,45 In the presence of accumulating data indicating 
potential harm, regulatory authorities have increasingly 
restricted approved indications for ESA use. These concerns 
relate primarily to thromboembolic events (TEEs), possible 
enhanced tumor progression, and reduced overall survival. 
Other toxicities of epoetin beta include hypertension, head-
ache and, rarely, pure red cell aplasia. Treatment-related 
ﬂ  u-like symptoms are uncommon and usually transient.22
Thromboembolic events
A recent meta-analysis evaluated the incidence of venous 
thromboembolism in 38 trials of ESAs including 8172 patients. 
The risk of venous thromboembolism was signiﬁ  cantly 
increased in patients receiving ESAs compared to control 
(RR 1.57; 95% CI 1.31–1.87).46 Similarly, a meta-analysis 
restricted to 12 trials of epoetin beta conﬁ  rmed that TEEs Therapeutics and Clinical Risk Management 2009:5 265
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were more common in patients receiving epoetin (0.22 events 
per patient-year) compared with control (0.14 events per 
patient-year).47 The enhanced risk of TEEs in patients with 
cancer- or cancer treatment-related anemia is consistent with 
the risk seen in other ESA indications including chronic renal 
failure48,49 and when used perioperatively.50
Speciﬁ  c risk factors for TEEs have not been deﬁ  ned. In 
particular, a conclusive relationship between TEE and either 
Hb level achieved or rate of Hb rise has not been deﬁ  nitively 
demonstrated in patients with cancer.37 The 2006 Agency for 
Healthcare Research and Quality meta-analysis identiﬁ  ed a 
trend for increasing risk with increased target Hb.36 However, 
the authors cautioned that TEE rates may have been under-
reported in many trials and that, crucially, individual patient data 
on Hb concentration preceding a TEE was not available. Glaspy 
and colleagues have started to address this with an analysis of 
individual patient-level data for 901 patients enrolled in 6 RCTs 
of darbepoetin to treat chemotherapy-induced anemia.51 In this 
exploratory analysis they examined the relationship of both 
achieved Hb level and rate of Hb increase to TEE. Achieving 
a Hb level  12 g/dL or an increase in Hb   1 g/dL in 14 days 
was associated with an increased risk of TEEs. It is hoped that 
an updated Cochrane analysis utilizing individual patient data 
will provide more deﬁ  nitive evidence on this point. At present 
both ASCO/ASH and ESMO guidelines recommend that each 
patient’s baseline thromboembolic risk is taken into account 
when considering the risk: beneﬁ  t ratio for commencing ESA 
therapy.25,26 Whether anti-platelet or anticoagulant therapy may 
have a role in modulating the risk of TEE is unknown.52
Overall survival/tumor progression
Signiﬁ  cant concerns regarding a possible negative impact 
of ESA therapy on cancer patient outcomes first arose 
in 2003 with the publication of 2 randomized controlled 
trials demonstrating increased mortality in patients receiv-
ing epoetin beta (ENHANCE)31 or epoetin alfa (BEST),53 
respectively. In contrast to earlier studies both of these trials 
prospectively evaluated survival (progression free or overall) 
as a primary endpoint.
In the ENHANCE trial Henke and colleagues random-
ized patients with head and neck cancer undergoing radio-
therapy to epoetin beta or placebo. Mean Hb concentration 
in the treatment arm was 11.7 g/dL at baseline rising to 
14.8 g/dL at 4 weeks and 15.4 g/dL at 9 weeks. Both locore-
gional progression (RR 1.69; 95% CI 1.16–2.47) and death 
(RR 1.39; 95% CI 1.05–1.84) were more likely in the treat-
ment arm. The BEST trial randomized patients who were 
receiving ﬁ  rst-line chemotherapy for metastatic breast cancer 
to epoetin alfa or placebo with the aim of maintaining Hb in 
the range 12 to 14 g/dL. Treatment was initiated if baseline 
or on-treatment Hb was  13 g/dL. This trial was terminated 
early after an interim analysis revealed an excess in 12 month 
mortality (the primary endpoint) in patients receiving epo-
etin (76% versus 70% in control arm, p = 0.0117). Whilst 
the designs of both of these trials have been heavily criti-
cized,53–56 their ﬁ  ndings were sufﬁ  cient to prompt an FDA 
Oncologic Drug Advisory Committee (ODAC) to recom-
mend that further studies be performed to identify risks 
associated with ESAs. Speciﬁ  cally these studies were to be 
double-blind placebo-controlled trials recruiting patients 
with homogenous tumor types and with survival as primary 
endpoint. It was also recommended that incidence of TEEs 
be incorporated as a prospectively deﬁ  ned endpoint. Since 
2004 accruing data has prompted two further ODAC meet-
ings, in May 2007 and March 2008. In addition to the BEST 
and ENHANCE trials, the March 2008 ODAC considered 
data from a further 6 studies.57 Four of these showed statisti-
cally signiﬁ  cant tumor progression and/or reduced survival 
and a further 2 studies demonstrated a non-signiﬁ  cant trend 
towards tumor progression and/or reduced survival. Of the 
8 studies considered, 4 utilized ESAs in patients receiving 
chemotherapy, 2 in conjunction with radiotherapy, and 2 in 
the absence of anti-cancer therapy.
The 20000161 trial randomized patients with lymphoid 
malignancies undergoing chemotherapy to receive darbepo-
etin or placebo.58 The primary endpoint was Hb response. The 
target Hb was 13 to 14 g/dL for woman and 13 to 15 g/dL 
for men. Six percent of patients on the darbepoetin arm died 
during or within 30 days of treatment versus 2% in the control 
arm. The hazard ratio (HR) for death was 1.37 (p = 0.04).46 
Most deaths were attributed to progressive disease.
The PREPARE trial randomized 733 patients with early 
breast cancer in a 2 × 2 factorial design to standard or dose dense/
dose intense chemotherapy and to darbepoetin or transfusion 
support with a target Hb of 12.5 to 13 g/dL.59 Comparison of 
relapse-free and overall survival of the ESA versus transfusion 
support arms was a secondary endpoint. Three-year relapse-
free and overall survival were lower in patients receiving 
darbepoetin with HRs of 1.42 (95% CI 0.93–2.18) and 1.33 
(95% CI 0.99–1.79) in favor of transfusion respectively.
The GOG-191 trial randomized 114 patients with stage 
2B to 4A cervical cancer who were receiving concur-
rent cisplatin and radiotherapy to either epoetin alfa or 
transfusion support.60 The target Hb was 12–14 g/dL. The 
primary endpoint was progression-free survival. The trial was 
terminated early due to an increase in TEEs. Subsequently, Therapeutics and Clinical Risk Management 2009:5 266
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3 year progression-free and overall survival were found 
to be higher in the transfusion group with HR of 1.06 
(95% CI 0.58–1.91) and 1.28 (95% CI 0.68–2.42).
The DAHANCA 10 trial randomized 522 patients 
with baseline Hb   14 g/dL who were undergoing radical 
radiotherapy for head and neck cancer to receive darbepo-
etin alfa.61 The primary outcome was locoregional disease 
control. The trial was terminated after planned interim 
analysis demonstrated signiﬁ  cantly reduced locoregional 
control (5-year actuarial loco-regional control 56% vs 69% 
[p = 0.02, RR: 1.44, 95% CI 1.06–1.96]) and disease-free 
survival (48% vs 63% for darbepoetin vs control, p = 0.004, 
RR: 1.49 [1.13–1.97]). A trend towards reduced overall 
survival was seen (38% vs 51% for darbepoetin and control 
respectively, p = 0.08, RR: 1.28 [0.98–1.68]).
Finally, 2 double blind RCTs studied ESAs for cancer-
related anemia in the absence of anti-cancer therapy. 
In EPO-CAN-20 patients with metastatic NSCLC and 
Hb   12.1 g/dL were randomized to epoetin alfa vs placebo 
with a target Hb of 12 to 14 g/dL.62 Primary endpoint was 
quality of life. An unplanned safety analysis undertaken 
after accrual of 70 patients revealed a signiﬁ  cant reduction in 
median survival in the epoetin arm (63 vs 129 days; HR, 1.84; 
p = 0.04), leading to termination of the trial. The 20010103 
trial randomized 989 patients with a variety of tumor types 
and Hb   11 g/dL to darbepoetin or placebo.63 Target Hb 
concentration was 12 to 13 g/dL and the primary endpoint 
was the incidence of blood transfusion. There was a signiﬁ  -
cant difference in survival between the two groups in favor 
of placebo (HR = 1.22; 95% CI, 1.03–1.45; p = 0.022).
In contrast other randomized trials have not reported 
excess mortality in patients receiving ESAs.38 For example, 
the BRAVE trial randomized 463 women with metastatic 
breast cancer and Hb   12.9 g/dL to receive epoetin 
beta or supportive care commencing simultaneously with 
anthracycline or taxane based chemotherapy.34 The tar-
get Hb concentration was 13 to 15 g/dL and the primary 
endpoint was overall survival. Although patients receiv-
ing epoetin beta experienced more TEEs (13% vs 6%, 
p = 0.12) there were no signiﬁ  cant differences in either 
survival or disease progression. Another study randomized 
343 patients with lymphoproliferative malignancy who 
were transfusion dependent and who had a mean baseline 
Hb of 9.2 g/dL to epoetin beta or placebo.64 With median 
follow-up of 27 months there was no signiﬁ  cant difference 
in survival.
Aapro and colleagues recently conducted a meta-analysis 
using individual patient data for 2297 patients entered 
into 12 randomized controlled trials conducted in patients 
receiving epoetin beta in conjunction with chemotherapy, 
radiotherapy or surgery.47 Long term follow-up data was 
limited with follow-up further than 28 days after the end 
of the study period available for only 4 of the 12 trials. For 
all 12 trials there was no signiﬁ  cant difference in overall 
survival between the epoetin and control arms. However, an 
analysis including only the 4 trials with long term follow-up 
demonstrated a trend to poorer survival in the epoetin arm 
(HR 1.13, 95% CI 0.98–1.31, p = 0.082). Similar results 
were obtained for disease progression with no difference 
between epoetin and control arms in the analysis of all 
12 studies but a trend towards increased disease progression 
in 3 trials for which long term follow-up data was available 
(HR 1.13, 95% CI 0.95–1.34, p = 0.165). In a pre-planned 
subgroup analysis of patients with baseline Hb   11 g/ dL 
(n = 1246) no difference in survival was demonstrated. 
Interestingly, patients with baseline Hb   11 g/dL demon-
strated a reduced risk of progression in the pooled analysis 
of 12 studies (HR 0.8, 95% CI 0.65–0.99, p = 0.041) and a 
trend towards reduced risk of progression in the 3 trials for 
which longer term data were available (HR = 0.85, 95% CI 
0.64–1.13, p = 0.267). Importantly, however, the largest and 
most recent meta-analysis of ESA therapy which included 
13,611 patients treated in 51 phase 3 trials (epoetin alfa 
or beta in 40 trials, darbepoetin in 11 trials) has identiﬁ  ed 
signiﬁ  cantly higher mortality in patients treated with ESAs 
versus control (HR 1.10; 95% CI 1.01–1.20; p = 0.03).46
The cause of increased mortality in patients with cancer 
exposed to ESA therapy is not clear but cannot be entirely 
attributed to increased TEEs. The identiﬁ  cation of EPO 
receptors on tumor cells taken together with observations 
of enhanced tumor progression raises the possibility that 
epoetins may directly stimulate tumor proliferation or 
survival. Preclinical data (recently reviewed by Arcasoy65) 
have demonstrated EPO-induced stimulation of prolifera-
tion, invasion and survival in a variety of cancer cell lines 
in vitro. However, preclinical models have so far failed to 
provide in vivo evidence for a detrimental effect of exog-
enous EPO on syngeneic or xenograft tumor progression. 
An apparent link between EPO-R expression on tumor cells 
and poor outcome in patients receiving epoetin beta within 
the ENHANCE trial has been strongly challenged,66–70 
primarily due to concerns relating to the speciﬁ  city of the 
EPO-R antibody but also because of imbalances in baseline 
characteristics which may have been further compounded 
by the availability of tissue for only a minority of the study 
population. Even so this intriguing ﬁ  nding clearly demands Therapeutics and Clinical Risk Management 2009:5 267
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further study as more robust tools with which to analyze 
EPO-R expression become available. The role of EPO-R 
signaling in host cells is also of interest with compelling in 
vivo data supporting a role for EPO-R signaling in tumor 
neovascularization.71,72
In considering the risk: beneﬁ  t ratio for epoetin beta 
therapy it is important to recognize that none of the 8 
trials considered by the March 2008 ODAC evaluated 
ESAs within their licensed indications; specifically 
excessively high Hb concentrations were targeted and/or 
ESAs were used in patients not receiving chemotherapy. 
Whether ESA therapy used within currently approved 
indications might avoid these negative effects remains a 
critically important but unanswered question. Certainly 
target Hb concentration does appear to be an important 
factor in the context of chronic renal failure where ESA 
therapy targeting a higher rather than lower Hb concen-
tration has been associated with increased cardiovascular 
events and mortality.48, 49 Nonetheless, the FDA view is 
that “There are no studies which clearly establish the 
effect of ESAs on survival or on tumor promotion when 
ESAs were administered in accordance with recom-
mended dose in product labeling across multiple cancer 
subtypes” and the black box warning approved by the 
FDA in November 2007 stated “the risks of decreased 
survival and tumor progression have not been excluded 
when ESAs are dosed to target Hb   12 g/dL”. Paradoxi-
cally, an exploratory FDA analysis of the 20000161 and 
20010103 trials demonstrated that despite high target 
Hb levels the median Hb levels actually achieved were 
 12 g/dL. In the 20000161 trial the median achieved Hb 
was 11.0 g/dL (interquartile range 9.8 to 12.1) whilst in the 
20010103 trial median achieved Hb was 10.6 g/dL (inter-
quartile range 9.4–11.8). The poorer survival observed 
in these two trials, in which the majority of patients did 
not have excessive Hb concentration, at least generates a 
hypothesis that there may not be a lower threshold below 
which ESAs are safe. These safety signals have prompted 
recent label changes by FDA and EMEA as discussed 
below. Although epoetin beta is not marketed in the USA 
and not under FDA jurisdiction their conclusions on ESA 
therapy are relevant nevertheless.
Pure red cell aplasia (PRCA)
PRCA is a rare complication of ESA therapy resulting from 
the production of anti-epoetin antibodies and characterized by 
sudden loss of response to ESA, severe anemia and low reticu-
locyte count. PRCA has been primarily associated with the use 
of a speciﬁ  c epoetin alfa preparation (Eprex®, Janssen-Cilag 
Ltd, Bucks, UK) in patients receiving hemodialysis.73
Current role of epoetin beta 
in chemotherapy-related anemia
Together with other ESAs, the role of epoetin beta in 
the treatment of chemotherapy-related anemia continues 
to evolve. Recently both the EMEA and the FDA have 
restricted the indications for ESAs based on concerns 
of enhanced tumor progression and decreased survival 
as discussed above. In July 2008 the FDA required the 
makers of ESAs available in the USA to update their labels 
to state, “ESAs are not indicated for patients receiving 
myelosuppressive therapy when the anticipated outcome 
is cure”.74 Similarly, in June 2008 the Committee for 
Medicinal Products for Human Use of the EMEA agreed 
that product labels for ESAs including epoetin beta should 
be updated to include a warning that “transfusion should 
be the preferred method for correcting anemia in cancer 
patients, especially those with a long life expectancy”.75 
This follows earlier guidance issued in October 2007 that 
epoetins should be used in the treatment of anemia only 
if associated with symptoms and stipulating a target Hb 
concentration for all epoetins of 10 g/dL to 12 g/dL with 
a warning not to exceed a concentration of 12 g/dL.76 It 
should be noted that these ESA label changes post-date 
the most recent ASCO/ASH,26 ESMO25 and EORTC77 
published guidelines but are reﬂ  ected in updated NCCN 
guidelines.78 Taking recent label changes into consideration 
the following recommendations can be made for the use 
of epoetin beta:
•  Epoetin beta may be indicated in the treatment of symp-
tomatic anemia (Hb   11 g/dL) in patients undergoing 
palliative chemotherapy. In this context the therapeutic 
goal is to reduce the need for blood transfusion.
•  Epoetin beta should not be used prophylactically to prevent 
anemia nor is epoetin beta approved for cancer-associated 
anemia in patients not receiving chemotherapy.
•  Where chemotherapy is given with curative intent the 
risk:beneﬁ  t ratio of epoetin therapy may be unfavorable 
and transfusion should be preferred.
•  In all settings the risk:beneﬁ  t ratio of transfusion versus 
epoetin therapy should be discussed with the patient.
•  Patients should be iron replete and intravenous iron sup-
plementation may be associated with enhanced response 
to ESA therapy.
•  Epoetin beta dose should be titrated to the minimum which 
avoids need for transfusion as per the product label.Therapeutics and Clinical Risk Management 2009:5 268
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•  Epoetin beta should be discontinued when Hb is  12 g/dL.
•  Epoetin beta should be discontinued within 4 weeks of 
completing the course of chemotherapy.
The cost of epoetin beta is also highly pertinent and local 
health economic assessment provides a further determinant 
of its use. For example, in a United Kingdom context the 
National Institute for Health and Clinical Excellence (NICE) 
estimated ESA therapy in most clinical settings to be associ-
ated with an prohibitively high incremental cost effectiveness 
ratio of between £30,000 to £53,000 (US$55,000 to 98,000) 
per additional quality adjusted life-year (QALY) gained.79
Conclusions
Epoetin beta has demonstrable efﬁ  cacy in raising Hb concen-
tration and reducing the need for transfusion in patients with 
chemotherapy-related anemia. Nonetheless, accumulating 
evidence of undesirable effects has led regulatory authorities 
to mandate increasing restrictions on the use of epoetin beta 
and other ESAs. Yet many fundamental questions relating 
to ESA therapy in chemotherapy-related anemia remain 
unanswered. These include:
•  What is the risk:beneﬁ  t ratio of ESA therapy when used to 
target Hb   12 g/dL? As alluded to above, the risk:beneﬁ  t 
ratio of ESA therapy, when used to target lower Hb 
concentrations has not been deﬁ  ned in prospective clinical 
studies in either curative or palliative settings.
•  Does tumor type inﬂ  uence the risk: beneﬁ  t ratio of ESA 
therapy? For example, the poorer outcomes observed in 
patients with breast or head and neck cancer have not 
been replicated in patients with small cell lung cancer.80,81 
Whether this truly indicates a role for disease type in 
determining outcomes with ESA therapy remains to 
be seen.
•  Is tumor EPO-R expression predictive of harm in 
patients receiving ESAs? This will require development 
of a robust and widely accepted assay for determination 
of EPO-R expression by tumors together with further 
preclinical investigation of the consequences of EPO-R 
signaling in cancer and stromal cells. The role of the 
tumor micro-environment in modulating EPO-R signal-
ing pathways must also be deﬁ  ned.
Although some of these points may be addressed pre-
clinically and by individual patient level meta-analysis 
of existing data, there is also a need for further placebo-
controlled randomized trials conducted in patients with 
homogenous malignancies and with survival and tumor 
response as endpoints. For now, the signiﬁ  cant degree of 
uncertainty regarding the risk: beneﬁ  t ratio of epoetin beta 
therapy justiﬁ  es the precautionary approach adopted by 
regulatory agencies as the optimal means of preserving 
patient safety.
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